-+ 0.00%
-+ 0.00%
-+ 0.00%

Lixte Biotechnology prices USD 16.57 million registered direct offering at USD 6.31/share

PUBT·06/03/2026 12:31:17
Listen to the news
Lixte Biotechnology prices USD 16.57 million registered direct offering at USD 6.31/share
  • Lixte Biotechnology Holdings launched a registered direct offering targeting USD 16.57 million, priced at-the-market under Nasdaq rules.
  • Deal set at USD 6.31 per common share; includes pre-funded warrants priced at USD 6.3099 with a USD 0.0001 exercise price.
  • Offering covers 2,625,362 shares of common stock plus pre-funded warrants exercisable for one share each.
  • Gross proceeds expected to be about USD 16.57 million; closing expected on or about June 3, 2026.
  • Proceeds earmarked for general corporate purposes, working capital, and strategic initiatives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.